



PRESS RELEASE

**Surgery Recognized As Effective Treatment
For Selected Type 2 Diabetes Patients**

Doha, December 16, 2009 – A first-of-its-kind consensus statement by 50 medical experts from around the world has pronounced surgery to be a legitimate and effective treatment for type 2 diabetes, bringing the procedure a significant step closer to wider use and acceptance.

The report, recently published in the *Annals of Surgery*, illustrates the findings of the first Diabetes Surgery Summit (DSS), an international conference held at the Catholic University of Rome, Italy, where more than 50 scientific and medical experts agreed on a set of guidelines and definitions to guide the use and study of gastrointestinal surgery to treat type 2 diabetes.

“This is very good news for people in Qatar and other Gulf countries where diabetes continues to be a major health concern,” says Bakr Nour, MD, professor of surgery at Weill Cornell Medical College in Qatar and vice chair of surgery at Weill Cornell Medical College in New York. “It is estimated that 15 to 20% of GCC nationals suffer from diabetes, though many may be unaware that they have it. The disease rates continue to rise both in adults and children, and prevalence among Qatari children has doubled in the past 10 years.”

“While more study has been recommended, consensus about surgery as an effective treatment for select patients with type 2 diabetes means that many more patients will be considered as candidates for the procedure,” says Dr. Nour. “It could mean a dramatic improvement in the quality of life for those patients for whom lifestyle changes and less invasive therapies prove insufficient.”

“The recommendations from the DSS are an opportunity to improve access to surgical options supported by sound evidence, while also preventing harm from inappropriate use of unproven procedures,” says the consensus paper’s lead author Dr. Francesco Rubino, director of the gastrointestinal metabolic surgery program at New York-Presbyterian Hospital/Weill Cornell Medical Center and associate professor of surgery at Weill Cornell Medical College.

Office of Public Affairs
WCMC-Q
Education City
P.O. Box 24144
Doha, Qatar

Michael Vertigans
Director
Phone: +974 492 8650
Fax: +974 492 8444
Email: miv2008@qatar-med.cornell.edu

Christopher Gibbons
Assistant Editor/Writer
Phone: +974 492 8651
Fax: +974 492 8657
Email: cag2027@qatar-med.cornell.edu

The article in the *Annals of Surgery* summarizes the mounting body of evidence showing that bariatric surgery effectively reverses type 2 diabetes in a high proportion of morbidly obese patients, sometimes within weeks or even days, well before the patients have lost a significant amount of body weight.

Currently, bariatric surgery is only available as a treatment for severe obesity, defined as a body mass index of 35 kg/m² or more, according to National Institutes of Health guidelines established in 1991. The consensus statement acknowledged that the cutoff is arbitrary and not supported by scientific evidence. “With an emphasis on caution and patient safety, the statement boldly advances a revolutionary concept, the legitimacy of gastrointestinal surgery as a dedicated treatment for type 2 diabetes in carefully selected patients,” explains Dr. Rubino.

Based on earlier studies and on clinical experience in other countries, Dr. Rubino and his colleagues have found that removing portions of the jejunum or duodenum — the upper part of the small intestine right below the stomach — leads to spontaneous improvement or even resolution of diabetes. The same holds true when the surgeon simply inserts a tube in that part of the intestine, allowing food to pass through without coming into contact with the area. These findings suggest that when food normally passes from the stomach into the upper end of the small bowel, it triggers a cascade of hormonal reactions that cause diabetes.

“Prevention will always be the best strategy to approach the global epidemic of diabetes,” says Dr. Rubino. “But gastrointestinal surgery promises to be an important addition to the treatments available, and its study may also allow us to understand the disease mechanism in depth. We can only prevent what we truly understand.”

Ends

NOTES TO EDITORS

Established in partnership with Qatar Foundation, WCMC-Q is part of Weill Cornell Medical College (WCMC), the first US institution to offer its MD degree overseas. WCMC-Q shares the tripartite mission of WCMC: a dedication to excellence in education, patient care, and biomedical research.

Office of Public Affairs
WCMC-Q
Education City
P.O. Box 24144
Doha, Qatar

Michael Vertigans
Director
Phone: +974 492 8650
Fax: +974 492 8444
Email: miv2008@qatar-med.cornell.edu

Christopher Gibbons
Assistant Editor/Writer
Phone: +974 492 8651
Fax: +974 492 8657
Email: cag2027@qatar-med.cornell.edu

WCMC-Q offers an innovative program of pre-medical and medical studies leading to the Cornell University MD degree. Teaching is by Cornell and Weill Cornell faculty, including physicians at Hamad Medical Corporation (HMC) who hold Weill Cornell appointments.

Faculty and staff of WCMC-Q and WCMC are building the research capacity of Qatar in partnership with Qatar Foundation, HMC, the Ministry of Health and other organizations, with a focus on high quality research in genetic and molecular medicine, women's and children's health, gene therapy, and vaccine development.

Website: www.qatar-weill.cornell.edu

About Qatar Foundation

Founded in 1995 by decree of His Highness Sheikh Hamad Bin Khalifa Al Thani, Emir of Qatar, Qatar Foundation is a non-profit organization focusing on education, scientific research and community development. Under Qatar Foundation's umbrella are Education City, which comprises elite universities, several academic and training programmes and Qatar Science and Technology Park, which boasts more than 21 world class companies involved in scientific research and development.

Chaired by Her Highness Sheikha Mozah bint Nasser Al Missned, Qatar Foundation also aims to enhance lives through community development initiatives including Doha Debates, Reach out To Asia and Al Jazeera Childrens Channel.

Joint venture partnerships in the areas of design, ICT, telecommunications, policy studies and event management contribute to fulfilling the objectives of Qatar Foundation.

Website: www.qf.org.qa

Office of Public Affairs
WCMC-Q
Education City
P.O. Box 24144
Doha, Qatar

Michael Vertigans
Director
Phone: +974 492 8650
Fax: +974 492 8444
Email: miv2008@qatar-med.cornell.edu

Christopher Gibbons
Assistant Editor/Writer
Phone: +974 492 8651
Fax: +974 492 8657
Email: cag2027@qatar-med.cornell.edu